ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 275 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $25,730 | -9.1% | 990 | 0.0% | 0.02% | -5.0% |
| Q1 2024 | $28,314 | -6.5% | 990 | 0.0% | 0.02% | -20.0% |
| Q4 2023 | $30,294 | +13.9% | 990 | 0.0% | 0.02% | +4.2% |
| Q3 2023 | $26,601 | -24.6% | 990 | 0.0% | 0.02% | -20.0% |
| Q2 2023 | $35,303 | +40.4% | 990 | 0.0% | 0.03% | +15.4% |
| Q1 2023 | $25,146 | -37.4% | 990 | 0.0% | 0.03% | -27.8% |
| Q4 2022 | $40,154 | +21.7% | 990 | 0.0% | 0.04% | +16.1% |
| Q3 2022 | $33,000 | -5.7% | 990 | 0.0% | 0.03% | +3.3% |
| Q2 2022 | $35,000 | -23.9% | 990 | 0.0% | 0.03% | -6.2% |
| Q1 2022 | $46,000 | -30.3% | 990 | 0.0% | 0.03% | -20.0% |
| Q4 2021 | $66,000 | +32.0% | 990 | +23.8% | 0.04% | +25.0% |
| Q3 2021 | $50,000 | -24.2% | 800 | 0.0% | 0.03% | -25.6% |
| Q2 2021 | $66,000 | +24.5% | 800 | 0.0% | 0.04% | +16.2% |
| Q1 2021 | $53,000 | -13.1% | 800 | 0.0% | 0.04% | -19.6% |
| Q4 2020 | $61,000 | +177.3% | 800 | +60.0% | 0.05% | +142.1% |
| Q3 2020 | $22,000 | +46.7% | 500 | +42.9% | 0.02% | +26.7% |
| Q2 2020 | $15,000 | – | 350 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ELEMENT CAPITAL MANAGEMENT LLC | 142,649 | $618,000 | 0.25% |
| ING GROEP NV | 808,229 | $3,500,000 | 0.07% |
| A.R.T. Advisors, LLC | 232,470 | $1,006,000 | 0.05% |
| OppenheimerFunds, Inc. | 3,000,000 | $12,990,000 | 0.02% |
| Edge Wealth Management LLC | 10,000 | $43,000 | 0.01% |
| First Allied Advisory Services, Inc. | 61,000 | $264,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 200,000 | $866,000 | 0.01% |
| MILLENNIUM MANAGEMENT LLC | 1,272,138 | $5,508,000 | 0.01% |
| D. E. Shaw & Co., Inc. | 971,768 | $4,208,000 | 0.01% |
| Virtu Financial LLC | 18,008 | $78,000 | 0.00% |